Statements (19)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:legal_case
|
gptkbp:clinical_trial |
NC T04212345
|
gptkbp:criteria |
adults aged 18 and older
previous treatment with anti-PD-1 therapy |
gptkbp:end_date |
2023-12-31
|
https://www.w3.org/2000/01/rdf-schema#label |
KEYNOTE-890
|
gptkbp:is_tested_for |
Phase 2
|
gptkbp:launch_date |
2020-01-01
|
gptkbp:location |
multiple sites
|
gptkbp:participants |
overall response rate
progression-free survival |
gptkbp:result |
not yet published
|
gptkbp:social_responsibility |
gptkb:healthcare_organization
|
gptkbp:sponsor |
gptkb:Merck_&_Co.
|
gptkbp:status |
ongoing
|
gptkbp:student_enrollment |
approximately 200 participants
|
gptkbp:treatment |
gptkb:Pembrolizumab
|
gptkbp:bfsParent |
gptkb:Onco_Sec_Medical
|
gptkbp:bfsLayer |
5
|